3 completed, 2 withdrawn, 1 terminated. 6 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Withdrawn 2, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow MEDI0457: new trials by email Literature Review of MEDI0457 trials Research Report on MEDI0457
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients MEDI0457, Durvalumab - HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-09-17 | 2022-07-29 | |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer MEDI0457, CELLECTRA®5P device, Durvalumab - Head and Neck Cancer, Human Papilloma Virus | Phase 1 / Phase 2 | Completed | MedImmune LLC | 35 | 2017-06-26 | 2022-08-25 |
| A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer INO-3112 vaccine, Radiotherapy (Extrernal beam radiotherapy + brachytherapy), Cisplatin chemotherapy - Uterine Cervical Neoplasms | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2016-05-01 | 2016-05-13 | |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma INO-3112, CELLECTRA™-5P - Head and Neck Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 22 | 2014-08-13 | 2021-01-22 |
| A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer INO-3112, CELLECTRA™-5P - Cervical Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 10 | 2014-06-06 | 2021-02-21 |
Uterine Cervical Neoplasms (3) · Neoplasm Metastasis (2) · Neoplasms (2) · Oropharyngeal Neoplasms (2) · Recurrence (2) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Head and Neck Neoplasms (1) · Penile Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Inovio Pharmaceuticals (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · M.D. Anderson Cancer Center (1) · MedImmune LLC (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (5) · Switzerland (1)
Jeffrey Skolnik, MD (2) · Carole Fakhry, MD, MPH (1) · Fernanda Herrera (1) · George Coukos (1) · Michael M Frumovitz (1)
2015 (1)